Dick W, Lorenz W, Heintz D, Sitter H, Doenicke A
Klinik für Anästhesiologie, Johannes Gutenberg-Universität Mainz.
Anaesthesist. 1992;41(5):239-47.
In a controlled clinical trial in patients admitted for general surgery (mainly abdominal and thyroid), histamine release following nalbuphine 1 mg/kg i.v. versus fentanyl 5 micrograms/kg i.v. was studied in the course of an otherwise routine induction with promethazine/pethidine as premedication 30 min before the opioids and alcuronium-flunitrazepam-thiopental 5 min later. Succinylcholine was given before intubation and further analgesia was obtained by repeated administration of either nalbuphine or fentanyl. Plasma histamine levels were measured by a specific fluorometric assay, heart rate and blood pressure were measured for assessing hemodynamics, and clinical signs of anaphylactoid reactions such as skin eruptions and arrhythmias were registered. RESULTS. Nalbuphine and fentanyl both released histamine with an incidence of more than 40%. In addition, nalbuphine potentiated the histamine release evoked by the sequential administration of alcuronium-flunitrazepam-thiopental in one complex of application. The incidence of histamine release in the nalbuphine group was 6/13 = 46%, in the fentanyl group only 1/11 = 9% (chi2 test, P less than 0.05). Furthermore, this study showed high histamine levels after succinylcholine and intubation in a relation to time of administration that suggested histamine release as a stress response to intubation. Finally, the incidence of histamine release after a second injection of the opioids was still 30%. A direct correlation between plasma histamine levels, hemodynamic changes, and skin reactions could not be shown. A detailed causality analysis with histamine release as a contributory determinant showed histamine release less detrimental to hemodynamic stability than the opposite, which had been expected. However, the promethazine administered 30 min before induction of anaesthesia had strong H1- and H2-receptor antagonistic activity and was given with optimum timing for H1- and H2-prophylaxis. CONCLUSION. The study demonstrated that histamine release during anaesthesia and surgery depends strongly on the time sequence of drugs and measures used. Histamine release is not predictable from studies in human volunteers alone; studies in patients have to be added. Histamine release is not always detrimental. H3-receptor-mediated effects after H1- and H2-prophylaxis may help patients to counteract the effects of a series of vasoactive drugs given during induction of anaesthesia.
在一项针对普外科住院患者(主要是腹部和甲状腺手术)的对照临床试验中,研究了静脉注射1毫克/千克纳布啡与静脉注射5微克/千克芬太尼后的组胺释放情况。试验过程为:在使用阿库氯铵-氟硝西泮-硫喷妥钠诱导麻醉前30分钟,常规给予异丙嗪/哌替啶作为术前用药,5分钟后给予阿库氯铵-氟硝西泮-硫喷妥钠。插管前给予琥珀酰胆碱,通过重复注射纳布啡或芬太尼获得进一步的镇痛效果。采用特异性荧光测定法测量血浆组胺水平,测量心率和血压以评估血流动力学,并记录类过敏反应的临床体征,如皮疹和心律失常。结果:纳布啡和芬太尼均会释放组胺,发生率均超过40%。此外,在一组联合用药中,纳布啡增强了阿库氯铵-氟硝西泮-硫喷妥钠序贯给药诱发的组胺释放。纳布啡组组胺释放的发生率为6/13 = 46%,芬太尼组仅为1/11 = 9%(卡方检验,P < 0.05)。此外,本研究显示琥珀酰胆碱和插管后组胺水平与给药时间有关,提示组胺释放是对插管的应激反应。最后,再次注射阿片类药物后组胺释放的发生率仍为30%。未显示血浆组胺水平、血流动力学变化与皮肤反应之间存在直接相关性。以组胺释放作为促成决定因素进行的详细因果分析表明,组胺释放对血流动力学稳定性的损害小于预期的相反情况。然而,麻醉诱导前30分钟给予的异丙嗪具有较强的H1和H2受体拮抗活性,且给药时间对H1和H2预防最为合适。结论:该研究表明,麻醉和手术期间的组胺释放强烈依赖于所用药物和措施的时间顺序。组胺释放不能仅从人体志愿者研究中预测;必须增加患者研究。组胺释放并不总是有害的。H1和H2预防后的H3受体介导效应可能有助于患者抵消麻醉诱导期间给予的一系列血管活性药物的作用。